McKesson Corporation $MCK Shares Bought by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP raised its stake in McKesson Corporation (NYSE:MCK) by 156.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 53,198 shares of the company’s stock after buying an additional 32,482 shares during the period. McKesson accounts for approximately 2.1% of Fulcrum Asset Management LLP’s investment portfolio, making the stock its 4th largest position. Fulcrum Asset Management LLP’s holdings in McKesson were worth $46,007,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nvwm LLC raised its holdings in shares of McKesson by 933.3% during the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 28 shares during the period. Delos Wealth Advisors LLC acquired a new position in shares of McKesson during the 2nd quarter valued at about $27,000. Trellis Wealth Advisors LLC acquired a new position in shares of McKesson during the 3rd quarter valued at about $32,000. GK Wealth Management LLC purchased a new stake in shares of McKesson in the third quarter valued at about $38,000. Finally, Curry Webb Wealth Management LLC purchased a new stake in shares of McKesson in the third quarter valued at about $38,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Stock Performance

NYSE:MCK opened at $1,060.79 on Monday. The stock has a market capitalization of $122.48 billion, a P/E ratio of 27.28, a PEG ratio of 1.97 and a beta of 0.27. The company has a 50 day moving average price of $938.13 and a 200 day moving average price of $868.12. McKesson Corporation has a fifty-two week low of $723.68 and a fifty-two week high of $1,121.50.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $9.86 earnings per share. Research analysts forecast that McKesson Corporation will post 46.21 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s payout ratio is presently 9.67%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. Evercore reiterated an “outperform” rating and issued a $950.00 target price (down from $1,000.00) on shares of McKesson in a report on Thursday, August 6th. Wells Fargo & Company boosted their target price on shares of McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Leerink Partners increased their price target on shares of McKesson from $1,070.00 to $1,200.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Bank of America raised their price target on shares of McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,026.18.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Insiders Place Their Bets

In related news, EVP Francisco Fraga sold 650 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total value of $716,924.00. Following the sale, the executive vice president owned 4,414 shares in the company, valued at approximately $4,868,465.44. The trade was a 12.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO B Jr sold 111 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the sale, the chief accounting officer owned 521 shares in the company, valued at $464,445.45. This represents a 17.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,161 shares of company stock valued at $2,242,515 over the last ninety days. Insiders own 0.06% of the company’s stock.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.